• 1
    Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990; 212: 5159.
  • 2
    Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg. 1992; 215: 6877.
  • 3
    Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer. 1989; 63: 364367.
  • 4
    Spratt JS, Edwards M, Kubota T, Lindberg, R, Tsent MT. Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management. In: HickeyR, ClarkRL (editors). Current problems in cancer. Chicago: Yearbook Publishers, Inc, 1986: 558584.
  • 5
    Baines M, Oliver DJ, Carter RL. Medical management of intestinal obstruction in patients with advanced malignant disease. Lancet. 1985; 84: 990993.
  • 6
    Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998; 14: 254261.
  • 7
    Eilber FC, Rosen G, Forscher C, Nelson SD, Dorey FJ, Eilber FR. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999; 6: 645650.
  • 8
    Sugarbaker PH. Treatment of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy. In: SugarbakerPH, editor. Peritoneal carcinomatosis: principles of management. Boston: Kluwer Academic Publishers, 1996: 317335.
  • 9
    Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997; 8: 963968.
  • 10
    Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992; 69: 13341341.
  • 11
    Conlon KC, Casper ES, Brennan MF. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol. 1995; 2: 2631.
  • 12
    Dougherty MJ, Compton C, Talbert M, Wood WC. Sarcomas of the gastrointestinal tract: separation into favorable and unfavorable prognostic groups by mitotic count. Ann Surg. 1990; 214: 569574.
  • 13
    Zalupski M, Metch B, Balcerzote S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst. 1991; 83: 926932.
  • 14
    Antman KH, Ryan L, Elais A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989; 7: 126131.
  • 15
    Licht JD, Weissman LB, Antman K. Gastrointestinal sarcomas. Semin Oncol. 1988; 15: 181188.
  • 16
    Bevilacqua RG, Rogatko A, Hajdu SI, Brennan MF. Prognostic factors in retroperitoneal sarcomas. Arch Surg. 1991; 126: 328334.
  • 17
    Brennan MF, Casper ES, Harrison LB, Shiu MH, Gaynor J, Hajdu SI. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg. 1991; 214: 328338.